Three decades of discovery

As Neurocrine, our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders. Science is in our DNA—our founders were scientists, and their drive to discover is still felt as we continue to investigate potential treatments for rare diseases and conditions. We are motivated by people living with diseases and conditions that are without viable treatment options. We identify the greatest needs and work relentlessly to bring hope to those who need it most.

Our purpose

To relieve suffering for people with great needs.

Overview

Neurocrine is committed to transparency in its interactions. Neurocrine commits to following relevant pharmaceutical codes and has published details of its transfers of value to healthcare organisations. Where individual countries have other transparency regulations, Neurocrine's declarations for these can be found in the Transparency dropdown menu on a country-specific basis. Disclosures prior to 2025 are reported under the legacy name Diurnal.